IA
CTMX icon

IFP Advisors’s CytomX Therapeutics CTMX Stock Holding History

IFP Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-222
Closed -$5.67K – 3466
2023
Q1 		$5.67K Hold
222
– – ﹤0.01% 2513
2022
Q4 		$6K Hold
222
– – ﹤0.01% 3676
2022
Q3 		$6K Hold
222
– – ﹤0.01% 3921
2022
Q2 		$6K Hold
222
– – ﹤0.01% 3670
2022
Q1 		$6K Hold
222
– – ﹤0.01% 3670
2021
Q4 		$1K Hold
222
– – ﹤0.01% 2971
2021
Q3 		$1K Buy
+222
New +$1.19K ﹤0.01% 3003
2020
Q4 		– Sell
-78
Closed -$557 – 2974
2020
Q3 		$0 Buy
+78
New +$578 ﹤0.01% 2861
2018
Q3 		– Sell
-44
Closed -$1K – 3857
2018
Q2 		$1K Buy
+44
New +$1.12K ﹤0.01% 3703

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IFP Advisors's CTMX Position: Q2 2023 in Review

IFP Advisors sold out of CytomX Therapeutics (CTMX) in Q2 2023, closing a stake of 222 shares — an estimated $5.67K sold.

IFP Advisors first reported a position in CTMX in Q2 2018 and held it in 9 quarters. The position peaked at $6K in Q4 2022. 67 funds tracked by Wall St. Rank hold CTMX as of Q2 2023.

  • IFP Advisors reported no remaining CytomX Therapeutics position as of Q2 2023 after selling out during the quarter.
  • IFP Advisors sold 222 CytomX Therapeutics shares in Q2 2023, an estimated $5.67K.
  • IFP Advisors first reported a position in CytomX Therapeutics in Q2 2018 and held it in 9 quarters.
  • IFP Advisors's CytomX Therapeutics position peaked at $6K in Q4 2022.
  • 67 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2023.

Based on IFP Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.